Publications by authors named "Didier Autran"

Claim this Profile
A
Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.
Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Didier Autran

J Neurooncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Urinary Potassium Level Predicts High-dose Methotrexate Elimination Delay in Primary Central Nervous System Lymphoma.
Vincent Harlay, Alexandre Bertucci, Céline Boucard, Gregorio Petrirena, Chantal Campello, Didier Autran

Anticancer Res· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radio-chemotherapy feasibility for biopsy-only unresectable wild-type glioblastomas (BO-GBM).
Vincent Harlay, Romain Appay, Céline Bequet, Gregorio Petrirena, Chantal Campello, Didier Autran

Neurooncol Pract· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase III study of the European Organisation for Research and Treatment of Cancer Quality of Life cancer survivorship core questionnaire.
Marieke van Leeuwen, Jacobien M Kieffer, Teresa E Young, Maria Antonietta Annunziata, Volker Arndt, Didier Autran

J Cancer Surviv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adult H3K27M mutated thalamic glioma patients display a better prognosis than unmutated patients.
Stéphan Grimaldi, Vincent Harlay, Romain Appay, Céline Bequet, Grégorio Petrirena, Didier Autran

J Neurooncol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TEMOBIC: Phase II Trial of Neoadjuvant Chemotherapy for Unresectable Anaplastic Gliomas: An ANOCEF Study.
Emeline Tabouret, Michel Fabbro, Didier Autran, Khe Hoang-Xuan, Luc Taillandier

Oncologist· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of 3D volume growth rate for drug activity evaluation in meningioma clinical trials: the example of the CEVOREM study.
Thomas Graillon, Loic Ferrer, Jason Siffre, Marc Sanson, Matthieu Peyre, Didier Autran

Neuro Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.
Thomas Graillon, Marc Sanson, Chantal Campello, Ahmed Idbaih, Matthieu Peyre, Didier Autran

Clin Cancer Res· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leptomeningeal Gliomatosis: A Single Institution Study of 31 Patients.
Didier Autran, Maryline Barrie, Mona Matta, Colette Monserrat, Chantal Campello

Anticancer Res· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationships Between Dose Intensity, Toxicity, and Outcome in Patients with Oligodendroglial Tumors Treated with the PCV Regimen.
Emeline Tabouret, German Reyes-Botero, Caroline Dehais, Marine Daros, Maryline Barrie, Didier Autran

Anticancer Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis